Project: A novel targeted treatment against ovarian cancer
| Acronym | nOVAB (Reference Number: 113292) |
| Duration | 01/10/2019 - 03/10/2022 |
| Project Topic | We have discovered a specific epitope of a monoclonal antibody (mAb) that blocks a novel tumour cell-specific target, leading to cell death and reduced tumour growth via a novel cancer pathway. The nOVAB consortium aims to develop a mAb against the novel target into a treatment for solid tumours. Positioning of the mAb ultimately would be applicable in non-responders to immunotherapy. nOVAB’s focus on ovarian cancer is the first of solid tumours given there are few therapies available. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 11 |